Hp-normogram (normo-graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 Genotype

Helicobacter

Volumn 21, Issue 2, 2016, Pages 85-90

  Graham, David Y ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Helicobacter pylori; Antibiotic resistance; Antibiotic therapy; Duration; Normogram

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; CYTOCHROME P450 2C19; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFABUTIN; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANALYTIC METHOD; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ERADICATION THERAPY; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RELIABILITY; TREATMENT DURATION; TREATMENT RESPONSE; DRUG EFFECTS; GENETICS; HELICOBACTER INFECTIONS; MICROBIOLOGY; PROGNOSIS; TIME FACTOR; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2C19; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84959859856     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12287     Document Type: Article

References (21)

1. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.
2. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013;381:205-13.
3. Graham DY. Helicobacter pylori update: gastric cancer, reliable therapy, and possible benefits. Gastroenterology 2015;148:719-31.
4. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-57.
5. Bardhan K, Bayerdorffer E, Veldhuyzen van Zanten SJ, Lind T, Megraud F, Delchier JC, et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000;5:196-201.
6. Furuta T, Graham DY. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am 2010;39:465-80.
7. Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998;43(Suppl 1):S56-60.
8. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;5:321-31.
9. Villoria A, Garcia P, Calvet X, Gisbert JP, Vergara M. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008;28:868-77.
10. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012;36:414-25.
11. Sahara S, Sugimoto M, Uotani T, Ichikawa H, Yamade M, Iwaizumi M, et al. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther 2013;38:1129-37.
12. Vakil N, Lanza F, Schwartz H, Barth J. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004;20:99-107.
13. Murakami K, Sakura Y, Shiino M, Funao N, Nishimura A, Asaka M. Tu1056 a phase 3, double-blind study of a triple therapy with TAK-438, amoxicillin, and clarithromycin as first line eradication of H. pylori and a triple therapy with TAK-438, amoxicillin, and metronidazole as second line eradication of H. pylori. Gastroenterology 2014;146:S-740.
14. Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly. Gastroenterol Clin North Am 2015;44:537-63.
15. Liao J, Zheng Q, Liang X, Zhang W, Sun Q, Liu W, et al. Effect of fluoroquinolone resistance on 14-day levofloxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013;18:373-7.
16. Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter 2010;15:233-8.
17. Zhang W, Chen Q, Liang X, Liu W, Xiao S, Graham DY, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015;64:1715-20.
18. Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, et al. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial. Scand J Gastroenterol 2015;50:1185-90.
19. Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bastlein E, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003;8:310-9.
20. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson S, Kwon DH, et al. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther 2000;14:745-50.
21. Liang X, Xu X, Zheng Q, Zhang W, Sun Q, Liu W, et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol 2013;11:802-7.